BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chi H, Hansen BE, Yim C, Arends P, Abu-Amara M, van der Eijk AA, Feld JJ, de Knegt RJ, Wong DK, Janssen HL. Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther. 2015;41:867-876. [PMID: 25752878 DOI: 10.1111/apt.13150] [Cited by in Crossref: 68] [Cited by in F6Publishing: 71] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis 2019;86:201-7. [PMID: 31394205 DOI: 10.1016/j.ijid.2019.07.036] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Hsu Y, Mo L, Chang C, Wu M, Yang T, Kao J, Chen C, Tseng C, Tai C, Lin C, Wu C, Lin J. Serum viral load at the virological relapse predicts subsequent clinical flares in chronic hepatitis B patients off entecavir therapy: Clinical hepatitis B flare off entecavir. Journal of Gastroenterology and Hepatology 2017;32:1512-9. [DOI: 10.1111/jgh.13728] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li T, Liang Y, Zhang M, Liu F, Zhang L, Yang B, Wang L. Nucleoside/nucleotide analog consolidation therapy in hepatitis B e-antigen positive chronic hepatitis B patients: Three years should be preferred. Hepatol Res 2021;51:633-40. [PMID: 33772988 DOI: 10.1111/hepr.13641] [Reference Citation Analysis]
4 Liu LZ, Sun J, Hou J, Chan HLY. Improvements in the management of chronic hepatitis B virus infection. Expert Review of Gastroenterology & Hepatology 2018;12:1153-66. [DOI: 10.1080/17474124.2018.1530986] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Wübbolding M, Cornberg M, Höner zu Siederdissen C. Evidence-Based Approach to Stopping Oral Antiviral Therapy in Chronic HBV. Curr Hepatology Rep 2019;18:512-21. [DOI: 10.1007/s11901-019-00502-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Jeng WJ, Liaw YF. Finite Antiviral Therapy in Chronic Hepatitis B Patients with Cirrhosis. Semin Liver Dis 2021;41:349-57. [PMID: 34182587 DOI: 10.1055/s-0041-1729973] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Liaw YF. Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection. Nat Rev Gastroenterol Hepatol. 2019;16:631-641. [PMID: 31477873 DOI: 10.1038/s41575-019-0197-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
8 Papatheodoridi M, Papatheodoridis G. Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B. Cells. 2020;9. [PMID: 32093411 DOI: 10.3390/cells9020493] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
9 Tseng CH, Hsu YC, Chang CY, Tseng TC, Wu MS, Lin JT, Kao JH. Quantification of serum hepatitis B core antibody to predict off-entecavir relapse in patients with chronic hepatitis B. J Formos Med Assoc. 2017; Epub ahead of print. [PMID: 29249417 DOI: 10.1016/j.jfma.2017.11.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
10 Su TH, Kao JH. Unmet Needs in Clinical and Basic Hepatitis B Virus Research. J Infect Dis 2017;216:S750-6. [PMID: 29156048 DOI: 10.1093/infdis/jix382] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
11 Zhang L, Zhang FK. Treatment of chronic hepatitis B with tenofovir. Shijie Huaren Xiaohua Zazhi 2016; 24(31): 4279-4287 [DOI: 10.11569/wcjd.v24.i31.4279] [Reference Citation Analysis]
12 Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Reference Citation Analysis]
13 Liem KS, van Campenhout MJH, Xie Q, Brouwer WP, Chi H, Qi X, Chen L, Tabak F, Hansen BE, Janssen HLA. Low hepatitis B surface antigen and HBV DNA levels predict response to the addition of pegylated interferon to entecavir in hepatitis B e antigen positive chronic hepatitis B. Aliment Pharmacol Ther. 2019;49:448-456. [PMID: 30689258 DOI: 10.1111/apt.15098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
14 Hou J, Wang G, Wang F, Cheng J, Ren H, Zhuang H, Sun J, Li L, Li J, Meng Q, Zhao J, Duan Z, Jia J, Tang H, Sheng J, Peng J, Lu F, Xie Q, Wei L; Chinese Society of Hepatology, Chinese Medical Association., Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017;5:297-318. [PMID: 29226097 DOI: 10.14218/JCTH.2016.00019] [Cited by in Crossref: 109] [Cited by in F6Publishing: 59] [Article Influence: 21.8] [Reference Citation Analysis]
15 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
16 Tong MJ, Pan CQ, Han SB, Lu DS, Raman S, Hu KQ, Lim JK, Hann HW, Min AD. An expert consensus for the management of chronic hepatitis B in Asian Americans. Aliment Pharmacol Ther 2018;47:1181-200. [PMID: 29479728 DOI: 10.1111/apt.14577] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
17 Medas R, Liberal R, Macedo G. Discontinuation of antiviral therapy in chronic hepatitis B patients. World J Clin Cases 2021; 9(24): 6979-6986 [PMID: 34540953 DOI: 10.12998/wjcc.v9.i24.6979] [Reference Citation Analysis]
18 Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
19 Chien NH, Huang YT, Wu CY, Chang CY, Wu MS, Kao JH, Mo LR, Tai CM, Lin CW, Yang TH, Lin JT, Hsu YC. Time-varying serum gradient of hepatitis B surface antigen predicts risk of relapses after off-NA therapy. BMC Gastroenterol 2017;17:154. [PMID: 29221441 DOI: 10.1186/s12876-017-0697-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
20 Jeng WJ, Liu YC, Peng CW, Chien RN, Liaw YF. Highly significant differences in HBsAg kinetics among patients with two types of hepatitis B flare, with and without retreatment. J Antimicrob Chemother 2021:dkab360. [PMID: 34618028 DOI: 10.1093/jac/dkab360] [Reference Citation Analysis]
21 Pan HY, Pan HY, Chen L, Yang DH, Huang HJ, Tong YX, Chen CR, Yan J. Ten-year follow-up of hepatitis B relapse after cessation of lamivudine or telbivudine treatment in chronic hepatitis B patients. Clin Microbiol Infect 2015;21:1123.e1-9. [PMID: 26253290 DOI: 10.1016/j.cmi.2015.07.023] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
22 Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2021:gutjnl-2020-323979. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Chi H, Peng J, Janssen HLA. Reply. Clin Gastroenterol Hepatol 2019;17:1001-2. [PMID: 30902226 DOI: 10.1016/j.cgh.2018.10.005] [Reference Citation Analysis]
24 Cao J, Chi H, Yu T, Li Z, Hansen BE, Zhang X, Zhong C, Sun J, Hou J, Janssen HLA. Off-Treatment Hepatitis B Virus (HBV) DNA Levels and the Prediction of Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy in Patients With Chronic Hepatitis B: A Prospective Stop Study. J Infect Dis. 2017;215:581-589. [PMID: 28329347 DOI: 10.1093/infdis/jix025] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 6.8] [Reference Citation Analysis]
25 Van Hees S, Bourgeois S, Van Vlierberghe H, Sersté T, Francque S, Michielsen P, Sprengers D, Reynaert H, Henrion J, Negrin Dastis S, Delwaide J, Lasser L, Decaestecker J, Orlent H, Janssens F, Robaeys G, Colle I, Stärkel P, Moreno C, Nevens F, Vanwolleghem T; Belgian NA Stop Study Group. Stopping nucleos(t)ide analogue treatment in Caucasian hepatitis B patients after HBeAg seroconversion is associated with high relapse rates and fatal outcomes. Aliment Pharmacol Ther 2018;47:1170-80. [PMID: 29498078 DOI: 10.1111/apt.14560] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
26 Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
28 Kao JH, Jeng WJ, Ning Q, Su TH, Tseng TC, Ueno Y, Yuen MF. APASL guidance on stopping nucleos(t)ide analogues in chronic hepatitis B patients. Hepatol Int 2021;15:833-51. [PMID: 34297329 DOI: 10.1007/s12072-021-10223-5] [Reference Citation Analysis]
29 Liaw YF. Hepatitis B Flare After Cessation of Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B: To Retreat or Not to Retreat. Hepatology. 2021;73:843-852. [PMID: 32810321 DOI: 10.1002/hep.31525] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
30 Xie Y, Li M, Ou X, Zheng S, Gao Y, Xu X, Yang Y, Ma A, Li J, Huang Y, Nan Y, Zheng H, Feng B. HBeAg-positive patients with HBsAg  < 100 IU/mL and negative HBV RNA have lower risk of virological relapse after nucleos(t)ide analogues cessation. J Gastroenterol 2021;56:856-67. [PMID: 34292372 DOI: 10.1007/s00535-021-01812-0] [Reference Citation Analysis]
31 Coffin CS, Lee SS. New paradigms in hepatitis B management: only diamonds are forever. Br Med Bull 2015;116:79-91. [PMID: 26377741 DOI: 10.1093/bmb/ldv039] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
32 Liaw YF. Stopping Nucleos(t)ide Analogue Therapy in HBeAg-Negative Chronic Hepatitis B. Gastroenterology 2020;159:1186. [PMID: 32433984 DOI: 10.1053/j.gastro.2020.01.056] [Reference Citation Analysis]
33 Kho-herman SGR, Chan HL. Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when? Liver Research 2017;1:135-9. [DOI: 10.1016/j.livres.2017.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
34 Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther. 2015;42:1182-1191. [PMID: 26381928 DOI: 10.1111/apt.13409] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
35 Liem KS, Fung S, Wong DK, Yim C, Noureldin S, Chen J, Feld JJ, Hansen BE, Janssen HLA. Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study). Gut. 2019;68:2206-2213. [PMID: 31462554 DOI: 10.1136/gutjnl-2019-318981] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
36 Su T, Yang H, Tseng T, Liou J, Liu C, Chen C, Chen P, Chen D, Liu C, Kao J. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy. The Journal of Infectious Diseases 2018;217:1193-201. [DOI: 10.1093/infdis/jix690] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 8.5] [Reference Citation Analysis]
37 Jun BG, Lee SH, Kim HS, Kim SG, Kim YS, Kim BS, Jeong SW, Jang JY, Kim YD, Cheon GJ. Predictive Factors for Sustained Remission after Discontinuation of Antiviral Therapy in Patients with HBeAg-positive Chronic Hepatitis B. Korean J Gastroenterol. 2016;67:28-34. [PMID: 26809629 DOI: 10.4166/kjg.2016.67.1.28] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
38 Xia M, Liao G, Chen H, Wu Y, Fan R, Zhang X, Peng J. Plasma CXCL13 is a predictive factor for HBsAg loss and clinical relapse after discontinuation of nucleos(t)ide analogue treatment. Clin Immunol 2019;198:31-8. [PMID: 30503407 DOI: 10.1016/j.clim.2018.11.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
39 Song DS, Jang JW, Yoo SH, Kwon JH, Nam SW, Bae SH, Choi JY, Yoon SK. Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B. Clin Infect Dis 2021;73:e892-903. [PMID: 33417679 DOI: 10.1093/cid/ciab007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Liu SK, Seto W, Lai C, Yuen M. Hepatitis B: treatment choice and monitoring for response and resistance. Expert Review of Gastroenterology & Hepatology 2016;10:697-707. [DOI: 10.1586/17474124.2016.1145547] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Chan HLY. Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy. J Gastroenterol Hepatol 2019;34:501-6. [PMID: 30402981 DOI: 10.1111/jgh.14534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 6.7] [Reference Citation Analysis]
43 Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
44 Osiowy C, Coffin C, Andonov A. Review of Laboratory Tests used in Monitoring Hepatitis B Response to Pegylated Interferon and Nucleos(t)ide Analog Therapy. Curr Treat Options Infect Dis 2016;8:177-93. [PMID: 27547127 DOI: 10.1007/s40506-016-0080-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
45 Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
46 Xia M, Chi H, Wu Y, Hansen BE, Li Z, Liu S, Liao G, Zhang X, Zhou B, Hou J, Sun J, Janssen HLA, Peng J. Serum hepatitis B virus RNA level is associated with biochemical relapse in patients with chronic hepatitis B infection who discontinue nucleos(t)ide analogue treatment. Aliment Pharmacol Ther 2021;54:709-14. [PMID: 34275138 DOI: 10.1111/apt.16538] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
47 Chi H, Japhary A, de Man RA, de Knegt RJ, Janssen HLA, Hansen BE. Younger age and language barriers are associated with nonadherence to clinical follow-up in hepatitis B treatment. J Viral Hepat 2018;25:1216-9. [PMID: 29679439 DOI: 10.1111/jvh.12920] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
48 Wong D, Littlejohn M, Yuen L, Jackson K, Mason H, Bayliss J, Rosenberg G, Gaggar A, Kitrinos K, Subramanian M, Marcellin P, Buti M, Janssen HLA, Gane E, Locarnini S, Thompson A, Revill PA. HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients. Aliment Pharmacol Ther 2018;47:114-22. [PMID: 29023803 DOI: 10.1111/apt.14362] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
49 Zhang L, Zhang FK. Recent advances in treatment of chronic hepatitis B with entecavir. Shijie Huaren Xiaohua Zazhi 2017; 25(1): 7-16 [DOI: 10.11569/wcjd.v25.i1.7] [Reference Citation Analysis]
50 Al Ashgar H, Peedikayil MC, Al Quaiz M, Al Sohaibani F, Al Fadda A, Khan MQ, Thoralsson E, Al Thawadi S, Al Jedai A, Al Kahtani K. HBsAg clearance in chronic hepatitis B patients with add-on pegylated interferon alfa-2a to ongoing tenofovir treatment: A randomized controlled study. Saudi J Gastroenterol 2017;23:190-8. [PMID: 28611343 DOI: 10.4103/sjg.SJG_541_16] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
51 Sagnelli C, Sagnelli E. Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors. World J Clin Infect Dis 2019; 9(2): 11-22 [DOI: 10.5495/wjcid.v9.i2.11] [Cited by in CrossRef: 1] [Article Influence: 0.3] [Reference Citation Analysis]
52 Chi H, Wong D, Peng J, Cao J, Van Hees S, Vanwolleghem T, Qi X, Chen L, Feld JJ, de Knegt RJ, Hansen BE, Janssen HLA. Durability of Response After Hepatitis B Surface Antigen Seroclearance During Nucleos(t)ide Analogue Treatment in a Multiethnic Cohort of Chronic Hepatitis B Patients: Results After Treatment Cessation. Clinical Infectious Diseases 2017;65:680-3. [DOI: 10.1093/cid/cix353] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
53 Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis. 2018;19:561-571. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
54 Chi H, Hansen BE, Guo S, Zhang NP, Qi X, Chen L, Guo Q, Arends P, Wang JY, Verhey E, de Knegt RJ, Xie Q, Janssen HLA. Pegylated Interferon Alfa-2b Add-on Treatment in Hepatitis B Virus Envelope Antigen-Positive Chronic Hepatitis B Patients Treated with Nucleos(t)ide Analogue: A Randomized, Controlled Trial (PEGON). J Infect Dis 2017;215:1085-93. [PMID: 28329061 DOI: 10.1093/infdis/jix024] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
55 Chi H, Li Z, Hansen BE, Yu T, Zhang X, Sun J, Hou J, Janssen HLA, Peng J. Serum Level of Antibodies Against Hepatitis B Core Protein Is Associated With Clinical Relapse After Discontinuation of Nucleos(t)ide Analogue Therapy. Clin Gastroenterol Hepatol 2019;17:182-191.e1. [PMID: 29902645 DOI: 10.1016/j.cgh.2018.05.047] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
56 Lee IC, Sun CK, Su CW, Wang YJ, Chang HC, Huang HC, Lee KC, Huang YS, Perng CL, Liu YH, Chua CS, Lin YM, Lin HC, Huang YH. Durability of Nucleos(t)ide Analogues Treatment in Patients With Chronic Hepatitis B. Medicine (Baltimore) 2015;94:e1341. [PMID: 26266383 DOI: 10.1097/MD.0000000000001341] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
57 Deng R, Fan R, Sun J. Letter to the Editor: Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.04.022] [Reference Citation Analysis]
58 Shen S, Wong GL, Kuang Z, van Campenhout MJH, Fan R, Wong VW, Yip TC, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J, Chan HL. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir-treated patients with chronic hepatitis B. J Med Virol 2020;92:1206-13. [PMID: 31724212 DOI: 10.1002/jmv.25628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Chen CH, Hung CH, Wang JH, Lu SN, Lai HC, Hu TH, Lin CH, Peng CY. The Incidence of Hepatitis B Surface Antigen Loss Between Hepatitis B E Antigen-Negative Noncirrhotic Patients Who Discontinued or Continued Entecavir Therapy. J Infect Dis. 2019;219:1624-1633. [PMID: 30689910 DOI: 10.1093/infdis/jiy697] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
60 Kuo M, Hu T, Hung C, Wang J, Lu S, Tsai K, Chen C. Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019;49:218-28. [DOI: 10.1111/apt.15053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
61 Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther. 2015;42:243-257. [PMID: 26151841 DOI: 10.1111/apt.13272] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 11.0] [Reference Citation Analysis]
62 Liaw YF, Jeng WJ. Benefit of stopping finite nucleos(t)ide analogues therapy in chronic hepatitis B patients. Gut 2020;69:1898-9. [PMID: 31784470 DOI: 10.1136/gutjnl-2019-320341] [Reference Citation Analysis]
63 Hung C, Wang J, Lu S, Hu T, Lee C, Chen C. Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy. J Viral Hepat 2017;24:599-607. [DOI: 10.1111/jvh.12683] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
64 Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, Liaw YF. Clinical relapse after cessation of tenofovir therapy in HBeAg-negative patients. Clin Gastroenterol Hepatol. 2016; Jul 9. [Epub ahead of print]. [PMID: 27404969 DOI: 10.1016/j.cgh.2016.07.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
65 Papatheodoridi M, Su TH, Hadziyannis E, Liao CH, Orfanidou Α, Yang HC, Zachou K, Liu CJ, Kourikou A, Gatselis N, Manolakopoulos S, Dalekos G, Kao JH, Hadziyannis S, Papatheodoridis GV. Hepatocellular carcinoma after treatment cessation in non-cirrhotic HBeAg-negative chronic hepatitis B: A multicentre cohort study. Liver Int 2021. [PMID: 34890120 DOI: 10.1111/liv.15128] [Reference Citation Analysis]
66 Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019;4:296-304. [PMID: 30795958 DOI: 10.1016/s2468-1253(19)30015-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 5.7] [Reference Citation Analysis]
67 Huang H, Zhou W, Zhu H, Zhou P, Shi X. Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs. Toxicol Appl Pharmacol 2017;323:36-43. [PMID: 28322895 DOI: 10.1016/j.taap.2017.03.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
68 Chi H, Arends P, Reijnders JGP, Carey I, Brown A, Fasano M, Mutimer D, Deterding K, Oo YH, Petersen J, van Bommel F, de Knegt RJ, Santantonio TA, Berg T, Welzel TM, Wedemeyer H, Buti M, Pradat P, Zoulim F, Hansen BE, Janssen HLA; for the VIRGIL Surveillance Study Group (European surveillance network for vigilance against viral resistance). Flares during long-term entecavir therapy in chronic hepatitis B: Flares during entecavir. Journal of Gastroenterology and Hepatology 2016;31:1882-7. [DOI: 10.1111/jgh.13377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
69 Chen CH, Hung CH, Wang JH, Lu SN, Hu TH, Lee CM. Long-term incidence and predictors of hepatitis B surface antigen loss after discontinuing nucleoside analogues in noncirrhotic chronic hepatitis B patients. Clin Microbiol Infect. 2018;24:997-1003. [PMID: 29288020 DOI: 10.1016/j.cmi.2017.12.013] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
70 Chong CH, Lim SG. When can we stop nucleoside analogues in patients with chronic hepatitis B? Liver Int. 2017;37 Suppl 1:52-58. [PMID: 28052620 DOI: 10.1111/liv.13314] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
71 García-López M, Lens S, Pallett LJ, Testoni B, Rodríguez-Tajes S, Mariño Z, Bartres C, García-Pras E, Leonel T, Perpiñán E, Lozano JJ, Rodríguez-Frías F, Koutsoudakis G, Zoulim F, Maini MK, Forns X, Pérez-Del-Pulgar S. Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients. J Hepatol 2021;74:1064-74. [PMID: 33278456 DOI: 10.1016/j.jhep.2020.11.043] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
72 Jeng WJ, Chen YC, Chien RN, Sheen IS, Liaw YF. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018;68:425-434. [PMID: 29108132 DOI: 10.1002/hep.29640] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 25.0] [Reference Citation Analysis]
73 Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021; 13(9): 1042-1057 [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Reference Citation Analysis]
74 Cornberg M, Sandmann L, Protzer U, Niederau C, Tacke F, Berg T, Glebe D, Jilg W, Wedemeyer H, Wirth S, Höner Zu Siederdissen C, Lynen-Jansen P, van Leeuwen P, Petersen J; Collaborators:. S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11). Z Gastroenterol 2021;59:691-776. [PMID: 34255317 DOI: 10.1055/a-1498-2512] [Reference Citation Analysis]